PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35526313-7	2022	Specifically, there were significantly higher numbers of mutations detected in EGFR, KRAS and PIK3CA in plasma (p = 9.82 x 10-3, p = 3.14 x 10-5, p = 1.95 x 10-3) and EBC (p = 2.18 x 10-3, p = 2.28 x 10-4,p = 0.016) compared to tissue NGS.	NSC638702	167-170	KRAS proto-oncogene, GTPase	Homo sapiens	85-89	
32031993-12	2020	The EGFR p.L858R and KRAS p.G12C driver mutations were found in both the FFPE tissue specimens and the corresponding EBC samples of the lung adenocarcinoma patients.	NSC638702	117-120	KRAS proto-oncogene, GTPase	Homo sapiens	21-25	
22795503-8	2012	In NSCLC patients pre-surgery EBC R mut/wild KRAS of 0.20 +- 0.03 decreased by 1.3- and 3.7-times (p < 0.001) at 7th and 30th day and 10 EBC specimens at day 30th became negative.	NSC638702	30-33	KRAS proto-oncogene, GTPase	Homo sapiens	45-49	
22795503-8	2012	In NSCLC patients pre-surgery EBC R mut/wild KRAS of 0.20 +- 0.03 decreased by 1.3- and 3.7-times (p < 0.001) at 7th and 30th day and 10 EBC specimens at day 30th became negative.	NSC638702	140-143	KRAS proto-oncogene, GTPase	Homo sapiens	45-49	
22795503-10	2012	R mut/wild KRAS in EBC did not correlate with the blood and cancer ratios.	NSC638702	19-22	KRAS proto-oncogene, GTPase	Homo sapiens	11-15